T1	p 709 812	USA . PARTICIPANTS A total of 403 adult , daily smokers without contraindications to bupropion SR use .
T2	i 33 70	bupropion sustained-release treatment
T3	i 174 208	bupropion sustained-release ( SR )
T4	i 455 467	bupropion SR
T5	i 550 568	placebo-controlled
T6	i 587 599	bupropion SR
T7	i 794 806	bupropion SR
T8	i 875 924	9-week course of bupropion SR or placebo pill and
T9	i 936 997	eight brief individual counseling sessions or no counseling .
T10	i 1118 1127	post-quit
T11	i 1237 1259	bupropion SR treatment
T12	i 1487 1499	Bupropion SR
T13	i 1696 1708	bupropion SR
T14	i 1799 1808	bupropion
T15	o 315 365	withdrawal distress , cigarette craving , positive
T16	o 373 400	and subjective reactions to
T17	o 455 467	bupropion SR
T18	o 1011 1093	Ecological momentary assessment ratings of smoking behavior and putative mediators
T19	o 1280 1290	abstinence
T20	o 1303 1325	withdrawal distress or
T21	o 1340 1358	subjective effects
T22	o 1438 1445	craving
T23	o 1487 1507	Bupropion SR effects
T24	o 1511 1538	point-prevalence abstinence
T25	o 1601 1611	motivation
T26	o 1615 1619	quit
T27	o 1624 1637	self-efficacy